AIM: To investigate the correlation of serum C-reactive protein(CRP)-to-albumin(ALB)ratio(CAR)and neutrophil-to-lymphocyte count ratio(NLR)with pathological staging and prognosis of retinopathy of prematurity(ROP), and the predictive value of its combined testing for the prognosis of infants.METHODS:Prospective study. A total of 147 children with ROP who were born in our hospital from March 2022 to September 2024 were served as the ROP group, and 100 premature infants without ROP were served as the control group in the same period. Fully automatic biochemical analyzer was used to detect serum CRP and ALB; the flow cytometry nucleic acid fluorescence staining was used to count neutrophils and lymphocytes, and the CAR and NLR were calculated. Spearman correlation was used to analyze the relationship of serum CAR and NLR with ROP staging. Logistic regression was used to analyze the factors affecting the prognosis of children with ROP. ROC curve was drew to analyze the predictive value of serum CAR and NLR for the prognosis of ROP.RESULTS: There was comparability between the ROP group and the control group. The ROP group had significantly higher serum CRP, CAR, neutrophil count, and NLR than the control group, and clearly lower ALB and lymphocyte count than the control group(all P<0.05). Children with stage IV ROP had clearly higher serum CAR and NLR than stages I, II, and III, and the differences among stages I, II, and III were significant(all P<0.05). Serum CAR and NLR were positively correlated with ROP staging(r=0.529, 0.587, all P<0.05), and there was a positive correlation between serum CAR and NLR(r=0.546, P<0.05). The poor prognosis group had clearly higher serum CAR and NLR than good prognosis group(all P<0.001). Elevated serum CAR and NLR were risk factors affecting the prognosis of children with ROP(all P<0.05). The AUC of serum CAR, NLR, and joint detection in predicting the prognosis of ROP children was 0.803, 0.825, and 0.938, respectively. The joint detection showed better predictive performance(Zcombinatoion-CAR=2.637, Zcombinatoion-NLR=2.528, all P<0.05).CONCLUSION:Serum CAR and NLR are elevated in children with ROP, and they are closely related to pathological staging and prognosis. The joint detection has a higher predictive value in evaluating the prognosis of ROP.

Objective:To assess the feasibility and efficacy of transperineal laser ablation(TPLA)with single laser fiber in treating benign prostatic obstruction(BPO).Methods:From April 2021 to March 2024,a total of 13 BPO patients were selected from Beijing Friendship Hospital.TPLA was performed using a single laser fiber,which was guided by transrectal biplane ultrasound.The single laser fiber was used to undergo TPLA under the guidance of trans-rectal dual-plane ultrasound.The intraoperative time,ablation time,energy consumption,indwelling time of catheter,and complications were observed.The postoperative 6 months was chosen as the cut-off point of follow-up,and the pre and postoperative changes of international prostate symptom score(IPSS),quality of life index(QoL),prostate volume(PV),residual urine volume(RUV)and the maximum urine flow rate(Qmax)were compared.Results:All 13 patients successfully underwent TPLA with single laser fiber.The average operation time was(55.1±18.3)min,and the average ablation time was(16.3±1.7)min,and average energy consumption was(3951.6±459.7)J,and the median value of indwelling time of catheter was 7(7,10)days.The number of postoperative complication was 2 cases,and both them belonged to Clavien-Dindo grade II complication.At the postoperative 6th month,the IPSS,QoL,PV,Qmax and RUV of all patients were improved,all of which were better than preoperative these indicators,and the differences were significant(t=12.102,-3.228,-3.181,-2.581,-2.936,P<0.05).Conclusion:The application of single laser fiber in conducting TPLA operation is feasibility at technical aspect,and it can achieve the therapeutic goals of improving patients'symptoms and enhancing their quality of life.Although its operational time is slightly longer than that of using multiple fibers simultaneously,it can effectively reduce the cost of expenditure for consumables.

Objective:To explore the efficacy and safety of brain radiotherapy combined with pyrotinib and capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases.Methods:Clinical data of 30 HER2-positive breast cancer patients with brain metastases treated at the Fourth Hospital of Hebei Medical University between January 2018 and January 2024 were retrospectively analyzed. According to the timing of drug administration, patients were divided into the concurrent radiotherapy and medication group ( n=20) and the sequential group receiving pyrotinib plus capecitabine within 1 month before or after radiotherapy ( n=10). Intracranial progression-free survival (iPFS), intracranial and extracranial objective response rates (ORR), overall survival (OS), and treatment safety were analyzed. Survival curves were plotted using the Kaplan-Meier method, and survival differences were compared by log-rank test. Results:The median follow-up time was 23.5 months (range, 5.2-37.8), with a median iPFS of 13.0 months (range, 1.7-27.3) and a median OS of 28.2 months (range, 7.3-46.2). The 1-year iPFS and OS in the concurrent radiotherapy with pyrotinib and capecitabine group were numerically higher than those in the sequential group treated within 1 month before or after radiotherapy, but the differences were not statistically significant ( P=0.825, 0.724, respectively). The intracranial and extracranial ORRs were 83.3% and 64.3%, respectively. The most common grade ≥3 treatment-related adverse reactions were diarrhea (27%) and neutropenia (23%). Conclusions:Radiotherapy combined with pyrotinib and capecitabine provides prolonged survival benefits with acceptable safety in patients with HER2-positive breast cancer brain metastases. Compared to concurrent administration, pyrotinib plus capecitabine given within 1 month before or after radiotherapy does not appear to affect prognosis.

Objective:To assess the feasibility and efficacy of transperineal laser ablation(TPLA)with single laser fiber in treating benign prostatic obstruction(BPO).Methods:From April 2021 to March 2024,a total of 13 BPO patients were selected from Beijing Friendship Hospital.TPLA was performed using a single laser fiber,which was guided by transrectal biplane ultrasound.The single laser fiber was used to undergo TPLA under the guidance of trans-rectal dual-plane ultrasound.The intraoperative time,ablation time,energy consumption,indwelling time of catheter,and complications were observed.The postoperative 6 months was chosen as the cut-off point of follow-up,and the pre and postoperative changes of international prostate symptom score(IPSS),quality of life index(QoL),prostate volume(PV),residual urine volume(RUV)and the maximum urine flow rate(Qmax)were compared.Results:All 13 patients successfully underwent TPLA with single laser fiber.The average operation time was(55.1±18.3)min,and the average ablation time was(16.3±1.7)min,and average energy consumption was(3951.6±459.7)J,and the median value of indwelling time of catheter was 7(7,10)days.The number of postoperative complication was 2 cases,and both them belonged to Clavien-Dindo grade II complication.At the postoperative 6th month,the IPSS,QoL,PV,Qmax and RUV of all patients were improved,all of which were better than preoperative these indicators,and the differences were significant(t=12.102,-3.228,-3.181,-2.581,-2.936,P<0.05).Conclusion:The application of single laser fiber in conducting TPLA operation is feasibility at technical aspect,and it can achieve the therapeutic goals of improving patients'symptoms and enhancing their quality of life.Although its operational time is slightly longer than that of using multiple fibers simultaneously,it can effectively reduce the cost of expenditure for consumables.

Objective:To explore the efficacy and safety of brain radiotherapy combined with pyrotinib and capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases.Methods:Clinical data of 30 HER2-positive breast cancer patients with brain metastases treated at the Fourth Hospital of Hebei Medical University between January 2018 and January 2024 were retrospectively analyzed. According to the timing of drug administration, patients were divided into the concurrent radiotherapy and medication group ( n=20) and the sequential group receiving pyrotinib plus capecitabine within 1 month before or after radiotherapy ( n=10). Intracranial progression-free survival (iPFS), intracranial and extracranial objective response rates (ORR), overall survival (OS), and treatment safety were analyzed. Survival curves were plotted using the Kaplan-Meier method, and survival differences were compared by log-rank test. Results:The median follow-up time was 23.5 months (range, 5.2-37.8), with a median iPFS of 13.0 months (range, 1.7-27.3) and a median OS of 28.2 months (range, 7.3-46.2). The 1-year iPFS and OS in the concurrent radiotherapy with pyrotinib and capecitabine group were numerically higher than those in the sequential group treated within 1 month before or after radiotherapy, but the differences were not statistically significant ( P=0.825, 0.724, respectively). The intracranial and extracranial ORRs were 83.3% and 64.3%, respectively. The most common grade ≥3 treatment-related adverse reactions were diarrhea (27%) and neutropenia (23%). Conclusions:Radiotherapy combined with pyrotinib and capecitabine provides prolonged survival benefits with acceptable safety in patients with HER2-positive breast cancer brain metastases. Compared to concurrent administration, pyrotinib plus capecitabine given within 1 month before or after radiotherapy does not appear to affect prognosis.

Acute myeloid leukemia (AML) is a common malignant disease of the hematological system, with high EVI1 expression accounting for 8%-10% of adult AML. Studies have shown that high EVI1 expression plays an important role in the treatment and prognosis of AML. In recent years, researchers have continuously revealed the structure and role of EVI1, but its mechanism of mediating AML has not been fully clarified. Therefore, systematically exploring the role of EVI1 in AML may provide a useful reference for the precise treatment of AML patients with high EVI1 expression.

Objective:To evaluate the effectiveness and safety of fistula-tract lase closure (FiLaC TM) surgery combined with the infliximab (IFX) for treating complex perianal fistulizing Crohn's disease (pfCD) . Methods:A retrospective was conducted. Patients with pfCD undergoing FiLaC TM at Renji Hospital, Shanghai Jiaotong University School of Medicine between February 2019 and August 2020 were retrospectively enrolled. The preoperative protocol included seton drainage and pharmacological induction, utilizing IFX alone or in combination with immunosuppressants. After achieving remission in CD, patients underwent definitive surgery with FiLaC TM. Clinical outcomes and adverse events such as bleeding, pain, and fecal incontinence following FiLaC TM were recorded. The Wexner fecal incontinence score and Crohn's anal fistula quality of life scale (CAF-QoL) were assessed both preoperatively and 24 months postoperatively. Results:The study included 30 patients (23 males, 7 females) with a median age of 23.6 (18.0, 30.5) years. At 24 months postoperatively, 21 patients (70.0%) achieved clinical cure; 2 patients (6.7%) showed improvement; 2 patients (6.7%) did not heal, with one eventually healing after a repeat FiLaC TM procedure and the other requiring re-seton placement; 5 patients (16.7%) relapsed and required re-seton. The Wexner fecal incontinence score at 24 months postoperatively was lower compared to preoperative scores [2.0 (1.8, 3.0) vs. 2.0 (2.0, 3.0), P = 0.001]. The postoperative CAF-QoL scores were higher as compared to the preoperative score[39.5 (33.8, 62.3) vs. 37.5 (30.0, 56.3), P = 0.03]. There were no complications such as fecal incontinence, urinary incontinence, or bleeding postoperatively. Twenty-seven patients (90%) experienced mild pain, and 1 (3.3%) reported moderate pain, all resolving without intervention. Conclusion:Combined treatment with FiLaC TM and IFX is both effective and safe for managing complex pfCD.

Objective:To evaluate the effectiveness and safety of fistula-tract lase closure (FiLaC TM) surgery combined with the infliximab (IFX) for treating complex perianal fistulizing Crohn's disease (pfCD) . Methods:A retrospective was conducted. Patients with pfCD undergoing FiLaC TM at Renji Hospital, Shanghai Jiaotong University School of Medicine between February 2019 and August 2020 were retrospectively enrolled. The preoperative protocol included seton drainage and pharmacological induction, utilizing IFX alone or in combination with immunosuppressants. After achieving remission in CD, patients underwent definitive surgery with FiLaC TM. Clinical outcomes and adverse events such as bleeding, pain, and fecal incontinence following FiLaC TM were recorded. The Wexner fecal incontinence score and Crohn's anal fistula quality of life scale (CAF-QoL) were assessed both preoperatively and 24 months postoperatively. Results:The study included 30 patients (23 males, 7 females) with a median age of 23.6 (18.0, 30.5) years. At 24 months postoperatively, 21 patients (70.0%) achieved clinical cure; 2 patients (6.7%) showed improvement; 2 patients (6.7%) did not heal, with one eventually healing after a repeat FiLaC TM procedure and the other requiring re-seton placement; 5 patients (16.7%) relapsed and required re-seton. The Wexner fecal incontinence score at 24 months postoperatively was lower compared to preoperative scores [2.0 (1.8, 3.0) vs. 2.0 (2.0, 3.0), P = 0.001]. The postoperative CAF-QoL scores were higher as compared to the preoperative score[39.5 (33.8, 62.3) vs. 37.5 (30.0, 56.3), P = 0.03]. There were no complications such as fecal incontinence, urinary incontinence, or bleeding postoperatively. Twenty-seven patients (90%) experienced mild pain, and 1 (3.3%) reported moderate pain, all resolving without intervention. Conclusion:Combined treatment with FiLaC TM and IFX is both effective and safe for managing complex pfCD.

Objective:To compare the postoperative anorectal and urogenital function in patients undergoing Da Vinci robot vs laparoscopic total mesorectal excision (TME) for middle and low rectal cancer.Methods:A prospective controlled study was conducted to analyze the clinical data of 120 patients with middle and low rectal cancer receiving low anterior resection (Dixon procedure) at the Department of Gastrointestinal Surgery, Guizhou Provincial People's Hospital from Jun 2020 to Oct 2022, including 65 patients in the laparoscopic surgery group and 55 patients in the robotic surgery group.All patients underwent colonoscopy and pelvic MRI, and the distance of the tumor from the anal margin was less than 10 cm.The clinical data of the patients were collected and followed up by questionnaire at 12 months after operation. The anal defecation function was assessed by Wexner constipation score and low anterior resection syndrome scale (LARS).The urinary function was measured by International Prostate Symptom Score (IPSS) and International Advisory Committee on Urinary Incontinence Lower Urinary Tract Symptom Scale (ICIQ-MLUTS/ ICIQ-FluTS).Reproductive function was valued by International Index of Erectile Function (IIEF-5 score) was used for male function and the sexual function index (FIFS-19) for females.Results:The postoperative anal defecation function in robotic group was better than that of the laparoscopic group, and the LARS score was (4.3±2.2) vs. (9.8±1.5), t=9.151, P=0.038.There was no serious urinary dysfunction in neither groups. The robot group had a certain advantage in the protection of male urinary function [ICIQ-MLUTS, (1.8±5.8) vs. (13.8±4.9), t=4.128, P=0.038], while there was no significant difference in the female urinary function between the two groups .ICIQ-FLUTS [(-0.3±1.0) vs. (-0.2±0.9), t=0.015, P=0.844].There was no significant difference in reproductive function between the two groups, IIEF-5 score [(-13.4±2.7) vs. (-11.7±3.4), t=0.35, P=0.615]. FIFS-19 [(-5.2±4.6) vs. (-10.5±6.4), t=4.128, P=0.254]. Conclusions:Compared with laparoscopic surgery, robotic surgery has a better possibility of anal defecation after middle-low rectal cancer surgery. The robotic group has certain advantages in male urinary function protection, and the two surgical methods have similar effects on reproductive function protection.

【Objective】 To investigate the psychological status of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and to analyze the effects of anxiety on the total National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) in patients in Ngari Prefecture of Tibet. 【Methods】 CP/CPPS patients treated during Oct.2019 and Oct.2021 were involved and divided into anxiety group and non-anxiety group. The non-anxiety group received routine drug treatment, while the anxiety group received drugs and psychological intervention. 【Results】 A total of 117 patients were involved, including 68 in the anxiety group and 49 in the non-anxiety group. There were no statistical differences between the two groups in terms of age, body mass index (BMI), marital status, smoking history, and education level (P>0.05). The total NIH-CPSI score in the anxiety group (18.53±3.47) was higher than that in non-anxiety group (15.67±3.33), which was mainly manifested by the increase of pain and decrease of quality of life scores. Further stratification of anxiety level revealed that quality of life score and total NIH-CPSI score increased as anxiety symptoms worsened. After drug treatment, pain and urination symptoms were improved in the non-anxiety group, but the quality of life score and total NIH-CPSI score did not change significantly. After psychological intervention, the anxiety group had lower total NIH-CPSI score and other scores. 【Conclusion】 It is not uncommon for CP/CPPS patients to have a comorbidity of anxiety. The increase in the total NIH-CPSI score is caused by the increase of pain score and decrease of quality of life score. Active psychological intervention can improve anxiety, urinary symptoms, pain symptoms and quality of life.